Inhibitors of Microsomal Prostaglandin E2 Synthase-1 Enzyme as Emerging Anti-Inflammatory Candidates

Medicinal Research Reviews

Volumn 34, Issue 4, 2014, Pages 825-855

  Singh Bahia, Malkeet ^a   Kumar Katare, Yogesh ^b   Silakari, Om ^a   Vyas, Bhawna ^a   Silakari, Pragati ^c  

^a PUNJABI UNIVERSITY   (India)

^b Radharaman Institute of Pharmaceutical Sciences   (India)

^c ADINA Institute of Pharmaceutical Sciences   (India)

Author keywords

Atherosclerosis; Cancer; Cyclooxygenase 2 (COX 2); Osteoarthritis; Rheumatoid arthritis

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN INHIBITOR; BENZOXAZOLE DERIVATIVE; BIARYLIMIDAZOLE DERIVATIVE; DICLOFENAC; IBUPROFEN; IMIDAZOLE DERIVATIVE; IMIDAZOQUINOLINE DERIVATIVE; MICROSOMAL PROSTAGLANDIN E2 SYNTHASE 1 INHIBITOR; MONOMER; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENANTHRENE IMIDAZOLE DERIVATIVE; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRROLIZINE DERIVATIVE; ROFECOXIB; SODIUM; UNCLASSIFIED DRUG; UREA DERIVATIVE; WATER; ANTIINFLAMMATORY AGENT; ENZYME INHIBITOR; ISOMERASE; PROSTAGLANDIN E SYNTHASE;

ANEMIA; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CANCER CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COMPARATIVE EFFECTIVENESS; DISEASE EXACERBATION; DRUG DETERMINATION; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; ENZYME STRUCTURE; FEVER; HUMAN; MEMORY; NEOPLASM; NERVE CELL PLASTICITY; NEUROLOGIC DISEASE; NONHUMAN; OSTEOARTHRITIS; PAIN; PHYSIOLOGICAL PROCESS; PROSTAGLANDIN SYNTHESIS INHIBITION; REPRODUCTION; RHEUMATOID ARTHRITIS; SODIUM URINE LEVEL; SYNAPTIC TRANSMISSION; TISSUE DISTRIBUTION; WATER TRANSPORT; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; MICROSOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ENZYME INHIBITORS; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MICROSOMES;

EID: 84901820531     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21306     Document Type: Article

References (196)

1. 2 synthases. Clin Immunol 2006;119:229-240.
2. Smith WL. The eicosanoids and their biochemical mechanisms of action. Biochem J 1989;259:315-324.
3. Miller SB. Prostaglandins in health and disease: An overview. Semin Arthritis Rheum 2006;36:37-49.
4. Sugimoto Y, Narumiya S, Chikawa AI. Distribution and function of prostanoid receptors: Studies from knockout mice. Prog Lipid Res 2000;39:289-314.
5. Davies P, Bailey PJ, Goldenberg MM, Ford-Hutchinson AW. The role of arachidonic acid oxygenation products in pain and inflammation. Annu Rev Immonol 1984;2:335-357.
6. Samuelsson B, Morgenstern R, Jakobsson PJ. Membrane prostaglandin E synthase-1: A novel therapeutic target. Pharmacol Rev 2007;59:207-224.
7. 2 EP1 receptor mediates pain perception and regulates blood pressure. J Clin Invest 2001;107:325-331.
8. 2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis. Ann Neurol 2008;64:304-314.
9. Kurihara Y, Endo H, Akahoshi T, Kondo H. Up-regulation of prostaglandin E receptor EP2 and EP4 subtypes in rat synovial tissues with adjuvant arthritis. Clin Exp Immunol 2001;123:323-330.
10. 2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat Med 2009;15:633-640.
11. Jiang J, Quan Y, Ganesh T, Pouliot WA, Dudek FE, Dingledine R. Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation. Proc Natl Acad Sci USA 2013;110:3591-3596.
12. Honda T, Matsuoka T, Ueta M, Kabashima K, Miyachi Y, Narumiya S. Prostaglandin E(2)-EP(3) signaling suppresses skin inflammation in murine contact hypersensitivity. J Allergy Clin Immunol 2009;124:809-818.
13. Kunikata T, Yamane H, Segi E, Matsuoka T, Sugimoto Y, Tanaka S, Tanaka H, Nagai H, Ichikawa A, Narumiya S. Suppression of allergic inflammation by the prostaglandin E receptor subtype EP3. Nat Immunol 2005;6:524-531.
14. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenases-2. N Engl J Med 2001;345:433-442.
15. Allison MC, Howatson AG, Torrance CJ, Lee FD, Russel RI. Gastrointestinal damage associated with the use of non-steroidal anti-inflammatory drugs. N Engl J Med 1992;327:749-754.
16. Clive DM, Stoff JS. Renal syndromes associated with non-steroidal anti-inflammatory drugs. N Engl J Med 1984;310:563-572.
17. Jones R, Rubin G, Berenbaum F, Scheiman J. Gastrointestinal and cardiovascular risks of non-steroidal anti-inflammatory drugs. Am J Med 2008;121:464-474.
18. Masso Gonzalez EL, Patrignani P, Tacconelli S, Garcia Rodriguez LA. Variability among non-steroidal anti-inflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum 2010;62:1592-1601.
19. Henry D, Lim LL, Garcia Rodriguez LA, Perez Gutthann S, Carson JL, Griffin M, Savage R, Logan R, Moride Y, Hawkey C, Hill S, Fries JT. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis. Br Med J 1996;312:1563-1566.
20. Singh G, Wu O, Langhorne P, Madhok R. Risk of acute myocardial infarction with non-selective non-steroidal anti-inflammatory drugs: A meta analysis. Arthritis Res Ther 2006;8:1-8.
21. Hernandez-Diaz S, Varas-Lorenzo C, Garcia Rodriguez LA. Non-steroidal anti-inflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006;98:266-274.
22. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of anterothrombosis: Meta-analysis of randomized trials. Br Med J 2006;332:1302-1308.
23. 2 regulation of arachidonic acid mobilization. FEBS Lett 2002;531:2-6.
24. 2 enzymes: Classification and characterization. Biochim Biophys Acta 2000;1488:1-19.
25. Rebecchi MJ, Pentyala SN. Structure, function, and control of phosphoinositol-specific phospholipase C. Physiol Rev 2000;80:1291-1335.
26. Tang X, Edwards EM, Holmes BB, Falck JR, Campbell WB. Role of phospholipase C and diacylglyceride lipase pathway in arachidonic acid release and acetylcholine-induced vascular relaxation in rabbit aorta. Am J Physiol Heart Circ Physiol 2006;290:H37-H45.
27. Okazaki T, Sagawa N, Okita JR, Bleasdale JE, MacDonald PC, Johnston JM. Diacylglycerol metabolism and arachidonic acid release in human fetal membranes and decidua vera. J Biol Chem 1981;256:7316-7321.
28. Bell RL, Kennerly DA, Stanford N, Majerus PW. Diglyceride lipase: A pathway for arachidonate release from human platelets. Proc Natl Acad Sci USA 1979;76:3238-3241
29. Petrosino S, Ligresti A, Di Marzo V. Endocannabinoid chemical biology: A tool for the development of novel therapies. Curr Opin Chem Biol 2009;13:309-320.
30. Blankman JL, Cravatt BF. Chemical probes of endocannabinoid metabolism. Pharmacol Rev 2013;65:849-871.
31. Hwang J, Adamson C, Butler D, Janero DR, Makriyannis A, Bahr BA. Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: A neuroprotective therapeutic modality. Life Sci 2010;86:615-623.
32. Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MC, Ward AM, Hahn YK, Lichtman AH, Conti B, Cravatt BF. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 2011;334:809-813.
33. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120.
34. Dannhardt G, Kiefer W. Cyclooxygenase inhibitors: Current status and future prospects. Eur J Med Chem 2011;36:109-126.
35. Pham K, Hirschberg R. Global safety of Coxibs and NSAIDs. Curr Top Med Chem 2005;5:465-473.
36. Trebino CE, Stock JL, Gibbons CP, Naiman BM, Wachtmann TS, Umland JP, Pandher K, Lapointe JM, Saha S, Roach ML, Carter D, Thomas NA, Durtschi BA, McNeish JD, Hambor JE, Jakobsson PJ, Carty TJ, Perez JR, Audoly LP. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci USA 2003;100:9044-9049.
37. 2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 2000;275:32783-32792.
38. Radmark O, Samuelsson B. Microsomal prostaglandin E synthase-1 and 5-lipoxygenase: Potential drug targets in cancer. J Intern Med 2010;268:5-14.
39. Wang M, FitzGerald GA. The cardiovascular biology of microsomal prostaglandin E synthase-1. Trends Cardiovasc Med 2010;20:189-195.
40. Smith WL, Urade Y, Jakobsson. Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. Chem Rev 2011;111:5821-5865.
41. Chang HH, Meuillet EJ. Identification of mPGES-1 inhibitors: Where we are at? Fut Med Chem 2011;3:1909-1934.
42. Korotkova M, Jakobsson PJ. Microsomal prostaglandin E synthase-1 in rheumatic diseases. Front Pharmacol 2010;1:146.
43. 2 synthase-1 (mPGES-1): A novel anti-inflammatory therapeutic target. J Med Chem 2008;51:4059-4067.
44. 2 biosynthesis. J Biol Chem 2000;275:32775-32782.
45. Watanabe K, Kurihara K, Tokunaga Y, Hayaishi O. Two types of microsomal prostaglandin E synthase: Glutathione dependent and independent prostaglandin E synthases. Biochem Biophys Res Commun 1997;235:148-152.
46. Forsberg L, Leeb L, Thoren S, Morgenstern R, Jakobsson PJ, Human glutathione dependent prostaglandin E synthase: Gene structure and regulation. FEBS Lett 2000;471:78-82.
47. Ogino N, Miyamoto T, Yamamoto S, Hayaishi O. Prostaglandin endoperoxide E isomerase from bovine vesicular gland microsomes, a glutathione-requiring enzyme. J Biol Chem 1977;252:890-895.
48. Moonen P, Buytenhek M, Nugteren DH. Purification of PGH-PGE isomerase from sheep vesicular glands. Methods Enzymol 1982;86:84-91.
49. Ogorochi T, Ujihara M, Narumiya S. Purification and properties of prostaglandin H-E isomerase from the cytosol of human brain: Identification as anionic forms of glutathione S-transferase. J Neurochem 1987;48:900-909.
50. Meyer DJ, Muimo R, Thomas M, Coates D, Isaac RE. Purification and characterization of prostaglandin-H E-isomerase, a sigma-class glutathione S-transferase, from Ascaridia galli. Biochem J 1996;313:223-227.
51. Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B. Identification of human prostaglandin E synthase: A microsomal, glutathione dependent, inducible enzyme, constituting potential novel drug target. Proc Natl Acad Sci USA 1999;96:7220-7225.
52. Kobayashi T, Narumiya S. Function of prostanoid receptors: Studies on knockout mice. Prostaglandins Other Lipid Mediat 2002;68-69:557-573.
53. Chandrasekharan S, Foley NA, Jania L, Clark P, Audoly LP, Koller BH. Coupling of COX-1 to mPGES1 for prostaglandin E2 biosynthesis in the murine mammary gland. J Lipid Res 2005;46:2636-2648.
54. Stichtenoth DO, Thoren S, Bian H, Peters-Golden M, Jakobsson PJ, Crofford LJ. Microsomal prostaglandin E synthase is regulated by pro-inflammatory cytokines and glucocorticoids in primary rheumatoid synovial cells. J Immunol 2001;167:469-474.
55. Stark K, Bylund J, Torma H, Sahlen G, Oliw EH. On the mechanism of biosynthesis of 19-hydroxyprostaglandins of human seminal fluid and expression of cyclooxygenase-2, PGH 19-hydroxylase (CYP4F8) and microsomal PGE synthase-1 in seminal vesicles and vas deferens. Prostaglandins Other Lipid Mediat 2005;75:47-64.
56. Lazarus M, Eguchi N, Matsumoto S, Nagata N, Yano T, Killian GJ, Urade Y. Species-specific expression of microsomal prostaglandin E synthase-1 and cyclooxygenases in male monkey reproductive organs. Prostaglandins Leukot Essent Fatty Acids 2004;71:233-240.
57. Parent J, Chapdelaine P, Fortier MA. Molecular cloning and tissue distribution of microsomal-1 and cytosolic prostaglandin E synthases in macaque. Prostaglandins Other Lipid Mediat 2005;78:27-37.
58. Filion F, Bouchard N, Goff AK, Lussier JG, Sirois J. Molecular cloning and induction of bovine prostaglandin E synthase by gonadotropins in ovarian follicles prior to ovulation in vivo. J Biol Chem 2001;276:34323-34330
59. Sun T, Li SJ, Diao HL, Teng CB, Wang HB, Yang ZM. Cyclooxygenases and prostaglandin E synthases in the endometrium of the rhesus monkey during the menstrual cycle. Reproduction 2004;127:465-473.
60. Sun T, Deng WB, Diao HL, Ni H, Bai YY, Ma XH, Xu LB, Yang ZM. Differential expression and regulation of prostaglandin E synthases in the mouse ovary during sexual maturation and luteal development. J Endocrinol 2006;189:89-101.
61. Schneider A, Zhang Y, Zhang M, Lu WJ, Rao R, Fan X, Redha R, Davis L, Breyer RM, Harris R, Guan Y, Breyer MD. Membrane-associated PGE synthase-1 (mPGES-1) is co-expressed with both COX-1 and COX-2 in the kidney. Kidney Int 2004;65:1205-1213.
62. Mancini JA, Blood K, Guay J, Gordon R, Claveau D, Chan CC, Riendeau D. Cloning, expression, and up-regulation of inducible rat prostaglandin E synthase during lipopolysaccharide-induced pyresis and adjuvant-induced arthritis. Biol Chem 2001;276:4469-4475.
63. 2. Proc Natl Acad Sci USA 2008;105:11110-11115.
64. Ferguson AD, McKeever BM, Xu S, Wisniewski D, Miller DK, Yamin TT, Spencer RH, Chu L, Ujjainwalla F, Cunningham BR, Evans JF, Becker JW. Crystal structure of inhibitor bound human 5-lipoxygenase activating protein. Science 2007;317:510-512.
65. Holm PJ, Bhakat P, Jegerschold C, Gyobu N, Mitsuoka K, Fujiyoshi Y, Morgenstern R, Hebert H. Structural basis for detoxification and oxidative stress protection in membranes. J Mol Biol 2006;360:934-945.
66. Ago H, Kanaoka Y, Irikura D, Lam BK, Shimamura T, Austen KF, Miyano M. Crystal structure of a human membrane protein involved in cysteinyl leukotriene biosynthesis. Nature 2007;448:609-612.
67. Zhan CG, Huang X, Hamza A. Modeling of mPGES-1 three-dimensional structures: Applications in drug designing and discovery. US Patent Application No. 2011/0288844 A1.
68. Hamza A, Abdulhameed MD, Zhan CG. Understanding microscopic binding of human microsomal prostaglandin E synthase-1 with substrates and inhibitors by molecular modeling and dynamics simulation. J Phys Chem B 2008;112:7320-7329.
69. 2 and cofactor GSH: Insights from computational alanine scanning and site directed mutagenesis. J Phys Chem B 2010;114:5605-5616.
70. Huang X, Yan W, Gao D, Tong M, Tai HH, Zhan CG. Structural and functional characterization of human microsomal prostaglandin E synthase-1 by computational modeling and site directed mutagenesis. Bioorg Med Chem 2006;14:3553-3562.
71. Prage EB, Pawelzik SC, Busenlehner LS, Kim K, Morgenstern R, Jakobsson PJ, Armstrong RN. Location of inhibitor binding sites in the human inducible prostaglandin E synthase, mPGES1. Biochemistry 2011;50:7684-7693.
72. Pawelzik SC, Uda NR, Spahiu L, Jegerschold C, Stenberg P, Hebert H, Morgenstern R, Jakobsson PJ. Identification of key residues determining species difference in inhibitor binding of microsomal prostaglandin E synthase-1. J Biol Chem 2010;285:2954-2961.
73. MartinezMolina D, Wetterholm A, Kohl A, McCarthy AA, Niegowski D, Ohlson E, Hammarberg T, Eshaghi S, Haeggström JZ, Nordlund P. Structural basis for synthesis of inflammatory mediators by human leukotriene C4 synthase. Nature 2007;448:613-616.
74. Sali A, Blundell TL. Comparative protein modeling by satisfaction of spatial restrains. J Mol Biol 1993;234:779-815.
75. Yamada T, Komoto J, Watanabe K, Ohmiya Y, Takusagawa F. Crystal structure and possible catalytic mechanism of microsomal prostaglandin E synthase type 2 (mPGES-2). J Biol Chem 2005;348:1163-1176.
76. GuillénSchlippe YV, Hedstrom L. A twisted base? The role of arginine in enzyme catalyzed proton abstractions. Arch Biochem Biophys 2005;433:266-278.
77. 2α. J Biol Chem 2009;284:301-305.
78. 2 EP2 receptor. J Neurosci 2005;25:9858-9870.
79. 2 EP2 receptor. J Neurochem 2009;108:295-304.
80. 2 regulates membrane excitability and synaptic transmission in hippocampal CA1 pyramidal neurons. J Neurophysiol 2005;93:929-941.
81. Jia Z, Aoyagi T, Yang T. mPGES-1 protects against DOCA-salt hypertension via inhibition of oxidative stress or stimulation of NO/cGMP. Hypertension 2010;55:539-546.
82. Jia Z, Aoyagi T, Kohan DE, Yang T. mPGES-1 deletion impairs aldosterone escape and enhances sodium appetite. Am J Physiol Renal Physiol 2010;299:F155-F166.
83. Soodvilai S, Jia Z, Wang MH, Dong Z, Yang T. mPGES-1 deletion impairs diuretic response to acute water loading. Am J Physiol Renal Physiol 2009;296:F1129-F1135.
84. Sirois J, Lau J, Boerboom D, Antaya M. Prostaglandins and ovulation: From indomethacin to PGHS-2 knockout. In: EyA (Ed.), Ovulation: Evolving Scientific and Clinical Concepts. New York: Springer-Verlag; 2000. p 208-218.
85. Duffy DM, Seachord CL, Dozier BL. Microsomal prostaglandin E synthase-1 (mPGES-1) is the primary form of PGES expressed by the primate periovulatory follicle. Hum Reprod 2005;20:1485-1492.
86. 2 is a product of induced prostaglandin endoperoxide synthase 2 and microsomal type prostaglandin E synthase at the implantation site of the hamster. J Biol Chem 2004;279:30579-30587.
87. Kamei D, Murakami M, Nakatani Y, Ishikawa Y, Ishii T, Kudo I. Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis. J Biol Chem 2003;278:19396-19405.
88. Saha S, Engstrom L, Mackerlova L, Jakobsson PJ, Blomqvist A. Impaired febrile responses to immune challenge in mice deficient in microsomal prostaglandin E synthase-1. Am J Physiol Regul Integr Comp Physiol 2005;288:R1100-R1107.
89. Kamei D, Yamakawa K, Takegoshi Y, Mikami-Nakanishi M, Nakatani Y, Oh-Ishi S, Yasui H, Azuma Y, Hirasawa N, Ohuchi K, Kawaguchi H, Ishikawa Y, Ishii T, Uematsu S, Akira S, Murakami M, Kudo I. Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin E synthase-1. J Biol Chem 2004;279:33684-33695.
90. Engblom D, Saha S, Engstrom L, Westman M, Audoly LP, Jackobson PJ, Blomqvist A. Microsomal prostaglandin E synthase-1 is the central switch during immune induced pyresis. Nat Neurosci 2003;6:1137-1138.
91. Elander L, Engström L, Hallbeck M, Blomqvist A. IL-1β and LPS induce anorexia by distinct mechanisms differentially dependent on microsomal prostaglandin E synthase-1. Am J Physiol Regul Integr Comp Physiol 2007;292:R258-R267.
92. Pecchi E, Dallaporta M, Thirion S, Salvat C, Berenbaum F, Jean A, Troadec JD. Involvement of central microsomal prostaglandin E synthase-1 in IL-1β induced anorexia. Physiol Genomics 2006;25:485-492.
93. Bombardieri S, Cattani P, Ciabattoni G, Di Munno O, Pasero G, Patrono C, Pinca E, Pugliese F. The synovial prostaglandin system in chronic inflammatory arthritis: Differential effects of steroidal and nonsteroidal anti-inflammatory drugs. Br J Pharmacol 1981;73:893-901.
94. 2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. Arthritis Rheum 2002;46:1789-1803.
95. Masuko-Hongo K, Berenbaum F, Humbert L, Salvat C, Goldring MB, Thirion S. Up-regulation of microsomal prostaglandin E synthase-1 in osteoarthritic human cartilage: Critical roles of the ERK-1/2 and p38 signaling pathways. Arthritis Rheum 2004;50:2829-2838.
96. Kojima F, Naraba H, Miyamoto S, Beppu M, Aoki H, Kawai S. Membrane associated prostaglandin E synthase-1 is up-regulated by pro-inflammatory cytokines in chondrocytes from patients with osteoarthritis. Arthritis Res Ther 2004;6:R355-R365.
97. Liu HF, Li XH, Yang QD, Miao W, Qi SS, Song XM, He GS, Dong HL, Zhang FQ. COX-2 and mPGES-1 expression in carotid atherosclerotic plaques. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2007;24:453-456.
98. Wang M, Zukas AM, Hui Y, Ricciotti E, Pure E, Fitzgerald JA. Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc Natl Acad Sci USA 2006;103:14507-14512.
99. Plescia OJ, Smith AAH, Grinwich K. Subversion of immune system by tumor cells and role of prostaglandins. Proc Natl Acad Sci USA 1975;72:1848-1851.
100. Ben-Av P, Crofford LJ, Wilder RL, Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: A potential mechanism for inflammatory angiogenesis. FEBS Lett 1995;372:83-87.
101. 2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001;276:18075-18081.
102. Thun MJ, Namboodiri MM, Heath CW, Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-1596.
103. Garcia Rodriguez LA, Cea-Soriano L, Tacconelli S, Patrignani P. Coxibs: Pharmacology, toxicity and efficacy in cancer clinical trials. Recent Results Cancer Res 2013;191:67-93.
104. Yoshimatsu K, Altorki NK, Golijanin D, Zhang F, Jakobsson PJ, Dannenberg AJ, Subbaramaiah K. Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin Cancer Res 2001;7:2669-2674.
105. Oshima H, Oshima M, Inaba K, Taketo MM. Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice. EMBO J 2004;23:1669-1678.
106. VonRahden BH, Stein HJ, Hartl SA, Theisen J, Stigler B, Siewert JR, Sarbia M. Expression of prostaglandin E synthase in Barrett's cancer. Dis Esophagus 2008;21:304-308.
107. 2 synthase-1 in breast cancer: A potential target for therapy. J Pathol 2006;208:356-363.
108. Nardone G, Rocco A, Vaira D, Staibano S, Budillon A, Tatangelo F, Sciulli MG, Perna F, Salvatore G, Di Benedetto M, De Rosa G, Patrignani P. Expression of COX-2, mPGE-synthase-1, MDR-1 (P-gp), and Bcl-xL: A molecular pathway of H. pylori related gastric carcinogenesis. J Pathol 2004;202:305-312.
109. 2 biosynthesis is increased in human gastric cancer and during gastric carcinogenesis. Virchows Arch 2004;445:564-571.
110. Gudis K, Tatsuguchi A, Wada K, Hiratsuka T, Futagami S, Fukuda Y, Kiyama T, Tajiri T, Miyake K, Sakamoto C. Clinical significance of prostaglandin E synthase expression in gastric cancer tissue. Hum Pathol 2007;38:1826-1835.
111. Rocco A, Caruso R, Toracchio S, Rigoli L, Verginelli F, Catalano T, Neri M, Curia MC, Ottini L, Agnese V, Bazan V, Russo A, Pantuso G, Colucci G, Mariani-Costantini R, Nardone G. Gastric adenomas: Relationship between clinicopathological findings, Helicobacter pylori infection, APC mutations and COX-2 expression. Ann Oncol 2006;17:103-108.
112. Yoshimatsu K, Golijanin D, Paty PB, Soslow RA, Jakobsson PJ, DeLellis RA, Subbaramaiah K, Dannenberg AJ. Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin Cancer Res 2001;7:3971-3976.
113. 2, 15-prostaglandin dehydrogenase, and cyclooxygenase-2 expressions on tumor progression in colorectal cancer. Yonsei Med J 2010;51:692-699.
114. Takii Y, Abiru S, Fujioka H, Nakamura M, Komori A, Ito M, Taniguchi K, Daikoku M, Meda Y, Ohata K, Yano K, Shimoda S, Yatsuhashi H, Ishibashi H, Migita K. Expression of microsomal prostaglandin E synthase-1 in human hepatocelluar carcinoma. Liver Int 2007;27:989-996.
115. Nonaka K, Fujioka H, Takii Y, Abiru S, Migita K, Ito M, Kanematsu T, Ishibashi H. mPGES-1 expression in non-cancerous liver tissue impacts on postoperative recurrence of HCC. World J Gastroenterol 2010;16:4846-4853.
116. 2 production pathway in human pancreatic cancers. Pancreas 2008;37:121-127.
117. Mattila S, Tuominen H, Koivukangas J, Stenback F. The terminal prostaglandin synthases mPGES-1, mPGES-2, and cPGES are all over-expressed in human gliomas. Neuropathology 2009;29:156-165.
118. 2 pathway provides medulloblastoma therapeutic targets. Neuro Oncol 2008;10:661-674.
119. Gatalica Z, Lilleberg SL, Koul MS, Vanecek T, Hes O, Wang B, Michal M. COX-2 gene polymorphisms and protein expression in renomedullary interstitial cell tumors. Hum Pathol 2008;39:1495-1504.
120. 2 synthase-1 in papillary thyroid carcinoma. Acta Histochem Cytochem 2009;42:105-109.
121. Golijanin D, Tan JY, Kazior A, Cohen EG, Russo P, Dalbagni G, Auborn KJ, Subbaramaiah K, Dannenberg AJ. Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 are over-expressed in squamous cell carcinoma of the penis. Clin Cancer Res 2004;10:1024-1031.
122. Kawata R, Hyo S, Maeda T, Urade Y, Takenaka H. Simultaneous expression of cyclooxygenase-2 and microsomal prostaglandin E synthase in squamous cell carcinoma of the larynx. Acta Otolaryngol 2006;126:627-632.
123. 2 enzymatic pathways in cervical (pre)neoplastic lesions and functional consequences for antigen presenting cells. Cancer Immunol Immunother 2009;58:603-614.
124. 2 synthesis and signaling in malignant transformation and progression. Mol Cancer 2006;5:62.
125. 2 signaling for neurologic disease. Curr Med Chem 2008;15:1863-1869.
126. 2 as a therapeutic target for multiple sclerosis. Proc Natl Acad Sci USA 2009;106:21807-21812.
127. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial. JAMA 2003;289:2819-2826.
128. Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, Norman BA, Baranak CC. Rofecoxib: No effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004;62:66-71.
129. Scharf S, Mander A, Ugoni A, Vajda F, Christophidis NP. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999;53:197-201.
130. Rogers J, Kirby LC, Hempelman SR, Berry DL, Mcgeer PL, Kaszniak AW, Zalinski J, Cofield M, Mansukhani L, Willson P, Kogan F. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43:1609-1611.
131. de Jong D, Jansen R, Hoefnagels W, Jellesma-Eggenkamp M, Verbeek M, Borm G, Kremer B. No effect of one-year treatment with indomethacin on Alzheimer's disease progression: A randomized controlled trial. PLoS One 2008;3:e1475.
132. Sainati SM, Ingram DM, Talwalker S, Geis G. Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease. In 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy (Stockholm, Sweden); 2000; April 5-8, Abstract Book. p 180.
133. Soininen H, West C, Robbins J, Niculescu L. Long-term efficacy and safety of celecoxib in Alzheimer's disease. Dement Geriatr Cogn Disord 2007;23:8-21.
134. Pasqualetti P, Bonomini C, Dal Forno G, Paulon L, Sinforiani E, Marra C, Zanetti O, Rossini PM. A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease. Aging Clin Exp Res 2009;21:102-110.
135. Aisen PS, Schmeidler J, Pasinetti GM. Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology 2002;58:1050-1054.
136. Shie FS, Breyer RM, Montine TJ. Microglia lacking E prostanoid receptor subtype 2 have enhanced Abeta phagocytosis yet lack Abeta activated neurotoxicity. Am J Pathol 2005;166:1163-1172.
137. 2 EP3 receptors. Br J Pharmacol 2010;160:847-859.
138. Ikeda-Matsuo Y, Ota A, Fukada T, Uematsu S, Akira S, Sasaki Y. Microsomal prostaglandin E synthase-1 is a critical factor of stroke reperfusion injury. Proc Natl Acad Sci USA 2006;103:11790-11795.
139. NilupulPerera M, Ma HK, Arakawa S, Howells DW, Markus R, Rowe CC, Donnan GA. Inflammation following stroke. J Clin Neurosci 2006;13:1-8.
140. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of non-steroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993;90:11693-11697.
141. 2. Science 2002;296:539-541.
142. Topol EJ. Failing the public health: Rofecoxib, Merck and the FDA. N Engl J Med 2004;351:1707-1709.
143. FitzGerald GA. Coxibs and cardiovascular diseases. N Engl J Med 2004;351:1709-1711.
144. Cotter J, Wooltorton E. New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra). CMAJ 2005;172:1299.
145. Regner KR. Dual role of microsomal prostaglandin E synthase 1 in chronic kidney disease. Hypertension 2012;59:122-128.
146. Corey EJ, Nicolaou KC, Machida Y, Malmsten CL, Samuelsson B. Synthesis and biological properties of a 9, 11-azo-prostanoid: Highly active biochemical mimic of prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975;72:3355-3358.
147. 2 synthase-1. J Pharmacol Exp Ther 2008;326:975-982.
148. Rörsch F, Wobst I, Zettl H, Schubert-Zsilavecz M, Grösch S, Geisslinger G, Schneider G, Proschak E. Non-acidic inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1) identified by a multi-step virtual screening protocol. J Med Chem 2010;53:911-915.
149. Aquino M, Guerrero MD, Bruno I, Terencio MC, Paya M, Riccio R. Development of a second generation of inhibitors of microsomal prostaglandin E synthase 1 expression bearing the gamma hydroxybutenolide scaffold. Bioorg Med Chem 2008;16:9056-9064.
150. Ouellet M, Falgueyret JP, Ear PH, Pen A, Mancini JA, Riendeau D, Percival MD. Purification and characterization of recombinant microsomal prostaglandin E synthase-1. Protein Expr Purif 2002;26:489-495.
151. Thoren S, Jakobsson PJ. Coordinate up and down-regulation of glutathione dependent prostaglandin E synthase and cyclooxygenase-2 in A549 cells: Inhibition by NS-398 and leukotriene C4. Eur J Biochem 2000;267;6428-6834.
152. 2 synthase-1 and 5-lipoxygenase. J Med Chem 2008;51:8068-8076.
153. 2 and polyunsaturated fatty acids. Biochem Pharmacol 2002;63:1183-1189.
154. 2 synthase (mPGES-1) derived from MK-886. Bioorg Med Chem Lett 2005;15:3352-3355.
155. AbdulHameed MD, Hamza A, Liu J, Huang X, Zhan CG. Human microsomal prostaglandin E synthase-1 (mPGES-1) binding with inhibitors and the quantitative structure-activity correlation. J Chem Inf Model 2008;48:179-185.
156. Giroux A, Boulet L, Brideau C, Chau A, Claveau D, Cote B, Ethier D, Frenette R, Gagnon M, Guay J, Guiral S, Mancini J, Martins E, Massé F, Méthot N, Riendeau D, Rubin J, Xu D, Yu H, Ducharme Y, Friesen RW. Discovery of di-substituted phenanthreneimidazoles as potent, selective and orally active mPGES-1 inhibitors. Bioorg Med Chem Lett 2009;19:5837-5841.
157. Cote B, Boulet L, Brideau C, Claveau D, Ethier D, Frenette R, Gagnon M, Giroux A, Guay J, Guiral S, Mancini J, Martins E, Masse F, Methot N, Riendeau D, Rubin J, Xu D, Yu H, Ducharme Y, Friesen RW. Substituted phenanthreneimidazoles as potent, selective, and orally active mPGES-1 inhibitors. Bioorg Med Chem Lett 2007;17:6816-6820.
158. Chau A, Cote B, Ducharme Y, Frenette R, Friesen R, Gagnon M, Giroux A, Martins E, Yu H, Wu T. 2-(Phenyl or heterocyclin)-1H-phenenthro[9, 10-D]imadazoles as mPGES-1 inhibitors. US Patent No. US 7943649 B2 (2011).
159. Cote B, Ducharme Y, Frenette R, Friesen R, Giroux A, Martins E, Hamel P. Phenanthrene derivatives as mPGES-1 inhibitors. US Patent Application No. US 2009/0209571 A1.
160. Chau A, Cote B, Ducharme Y, Frenette R, Friesen R, Gagnin M, Giroux A, Martins E, Yu H, Hamel P. 2-(Phenyl or heterocyclic)-1H-phenanthro[9, 10D]imidazoles. US Patent Application No. 2009/0286772 A1.
161. 2 synthase-1. Bioorg Med Chem Lett 2010;20:6978-6982.
162. Chiasson JF, Boulet L, Brideau C, Chau A, Claveau D, Cote B, Ethier D, Giroux A, Guay J, Guiral S, Mancini J, Masse F, Methot N, Riendeau D, Roy P, Rubin J, Xu D, Yu H, Ducharme Y, Friesen RW. Tri-substituted ureas as potent and selective mPGES-1 inhibitors. Bioorg Med Chem Lett 2011;21:1488-1492.
163. Bahia MS, Silakari O. Exploring the biological Potential of urea derivatives against mPGES-1: A combination of quantum mechanics, pharmacophore modeling and QSAR analyses. Med Chem 2013;9:138-151.
164. Shiro T, Kakiguchi K, Takahashi H, Nagata H, Tobe M. Synthesis and biological evaluation of substituted imidazoquinoline derivatives as mPGES-1 inhibitors. Bioorg Med Chem 2013;21:2068-2078.
165. Shiro T, Takahashi H, Kakiguchi K, Inoue Y, Masuda K, Nagata N, Tobe M. Synthesis and SAR study of imidazoquinolines as a novel structural class of microsomal prostaglandin E2 synthase-1 inhibitors. Bioorg Med Chem Lett 2012;22:285-288.
166. Arhancet GB, Walker DP, Metz S, Fobian YM, Heasley SE, Carter JS, Springer JR, Jones DE, Hayes MJ, Shaffer AF, Jerome GM, Baratta MT, Zweifel B, Moore WM, Masferrer JL, Vazquez ML. Discovery and SAR of PF-4693627, a potent, selective, and orally bioavailable mPGES-1 inhibitor for the potential treatment of inflammation. Bioorg Med Chem Lett 2013;23:1114-1119.
167. Walker DP, Arhancet GB, Lu HF, Heasley SE, Metz S, Kablaoui NM, Franco FM, Hanau CE, Scholten JA, Springer JR, Fobian YM, Carter JS, Xing L, Yang S, Shaffer AF, Jerome GM, Baratta MT, Moore WM, Vazquez ML. Synthesis and biological evaluation of substituted benzoxazoles as inhibitors of mPGES-1: Use of a conformation-based hypothesis to facilitate compound design. Bioorg Med Chem Lett 2013;23:1120-1126.
168. 2 synthase-1 (mPGES-1) or as dual inhibitors of mPGES-1 and 5-lipoxygenase (5-LOX). J Med Chem 2009;52:4968-4972.
169. Hieke M, Greiner C, Thieme TM, Schubert-Zsilavecz M, Werz O, Zettl H. A novel class of dual mPGES-1/5-LO inhibitors based on the α-naphthylpirinixic acid scaffold. Bioorg Med Chem Lett 2011;21:1329-1333.
170. 2 synthase-1 (mPGES-1). J Med Chem 2011;54:3163-3174.
171. Guerrero MD, Aquino M, Bruno I, Riccio R, Terencio MC, Paya M. Anti-inflammatory and analgesic activity of a novel inhibitor of microsomal prostaglandin E synthase-1 expression. Eur J Pharmacol 2009;620:112-119.
172. Simone RD, Bruno I, Riccio R, Stadler K, Bauer J, Schaible AM, Laufer S, Werz O. Identification of new γ-hydroxybutenolides that preferentially inhibit the activity of mPGES-1. Bioorg Med Chem 2012;20:5012-5016.
173. Rorsch F, Buscato E, Deckmann K, Schneider G, Schubert-Zsilavecz M, Geisslinger G, Proschak E, Grosch S. Structure activity relationship of non-acidic quinazolinone inhibitors of human microsomal prostaglandin synthase-1 (mPGES-1). J Med Chem 2012;55:3792-3803.
174. Hamza A, Zhao X, Tong M, Tai HH, Zhan CG. Novel human mPGES-1 inhibitors identified through structure based virtual screening. Bioorg Med Chem 2011;19:6077-6086.
175. Kim WI, Choi KA, Do HS, Yu YG. Expression and purification of human mPGES-1 in E. coli and identification of inhibitory compounds from a drug library. BMB Rep 2008;41:808-813.
176. 2 synthase-1 (mPGES-1) inhibitors derived from an oxicam template. Bioorg Med Chem Lett 2010;20:1604-1609.
177. 2 synthase-1. Br J Pharmacol 2009;156:952-961.
178. Bauer J, Koeberle A, Dehm F, Pollastro F, Appendino G, Northoff H, Rossi A, Sautebin L, Werz O. Arzanol, a phenylated heterodimeric phloroglucinyl pyrone, inhibits eicosanoid biosynthesis and exhibits anti-inflammatory efficacy in vivo. Biochem Pharmacol 2011;81:259-268.
179. Bruno A, Di Francesco L, Coletta I, Mangano G, Alisi MA, Polenzani L, Milanese C, Anzellotti P, Ricciotti E, Dovizio M, Di-Francesco A, Tacconelli S, Capone ML, Patrignani P. Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)-benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes in vitro. Biochem Pharmacol 2010;79:974-981.
180. Mbalaviele G, Pauley AM, Shaffer AF, Zweifel BS, Mathialagan S, Mnich SJ, Nemirovskiy OV, Carter J, Gierse JK, Wang JL, Vazquez ML, Moore WM, Masferrer JL. Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor. Biochem Pharmacol 2010;79:1445-1454.
181. 2 synthase-1 and 5-lipoxygenase. J Pharmacol Exp Ther 2010;332:840-848.
182. 2 synthase-1. Eur J Med Chem 2012;48:153-163.
183. Pelcman B, Olofsson K, Arsenjans P, Ozola V, Suna E, Kalvins I. Thienopyrroles useful in the treatment of inflammation. US Patent Application No. 2009/077412 A1.
184. Pelcman B, Olofsson K, Habarova O, Andrianov V. Naphthalene disulfonamides useful for the treatment of inflammation. US Patent Application No. 2009/042817 A1.
185. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger ML. Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis. Lancet 2004;364:2021-2029.
186. McGettigan P, Henry D. Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: An examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med 2013;10:e1001388.
187. Rall JM, Mach SA, Dash PK. Intra-hippocampal infusion of a cyclooxygenase-2 inhibitor attenuates memory acquisition in rats. Brain Res 2003;968:273-276.
188. Teather LA, Packard MG, Bazan NG. Post-training cyclooxygenase-2 (COX-2) inhibition impairs memory consolidation. Learn Mem 2002;9:41-47.
189. Holscher C. Inhibitors of cyclooxygenases produce amnesia for a passive avoidance task in the chick. Eur J Neurosci 1995;7:1360-1365.
190. Shaw KN, Commins S, O'Mara SM. Deficits in spatial learning and synaptic plasticity induced by the rapid and competitive broad spectrum cyclooxygenase inhibitor ibuprofen are reversed by increasing endogenous brain-derived neurotrophic factor. Eur J Neurosci 2003;17:2438-2446.
191. Ae T, Ohno T, Hattori Y, Suzuki T, Hosono K, Minamino T, Sato T, Uematsu S, Akira S, Koizumi W, Majima M. Role of microsomal prostaglandin E synthase-1 in the facilitation of angiogenesis and the healing of gastric ulcers. Am J Physiol Gastrointest Liver Physiol 2010;299:G1139-G1146.
192. Jia Z, Wang H, Yang T. Microsomal prostaglandin E synthase 1 deletion retards renal disease progression but exacerbates anemia in mice with renal mass reduction. Hypertension 2012;59:122-128.
193. He S, Lai L. Molecular docking and competitive binding study discovered different binding modes of microsomal prostaglandin E synthase-1 inhibitors. J Chem Inform Model 2011;51:3254-3261.
194. Alvaro-Gracia JM. Licofelone: Clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis. Rheumatology 2004;43:i21-i25.
195. Information collected from http://www.prnewswire.com/news-releases/first-phase-iii-clinical-results-suggests-licofelone-ml3000-could-be-set-to-rival-cox-2-inhibitors-in-treatment-of-osteoarthritis-77885097.html.
196. Kulkarni SK, Singh VP. Licofelone: A novel analgesic and anti-inflammatory agent. Curr Top Med Chem 2007;7:251-263.